Presentations by Event

Presented at ID Week, San Francisco, October 2018

ETX2514SUL (Sulbactam/ETX2514) for The Treatment of Acinetobacter baumannii Infection

Isaacs R (IDWeek 2018)

Program(s): durlobactam (etx2514)

Presented at ASM Microbe, Atlanta, GA, June 2018

Addressing the Challenge of Gram-negative Permeation in Antibacterial Discovery

Thomas Durand-Reville, ASM Microbe 2018

Restoration of Sulbactam Activity by the Novel β-lactamase Inhibitor ETX2514 Against Recent Clinical Isolates of Acinetobacter baumannii, Including Extensively Drug-Resistant (XDR) Isolates Expressing OXA-237

Sarah McLeod, ASM Microbe 2018

Program(s): durlobactam (etx2514)

Evaluation of Pharmacokinetics/Pharmacodynamics of the Novel β-lactamase Inhibitor, ETX2514, in Combination with Sulbactam Against Acinetobacter baumannii

John O'Donnell, ASM Microbe 2018

Program(s): durlobactam (etx2514)

The Novel β-lactamase Inhibitor ETX1317 Effectively Restores the Activity of Cefpodoxime Against Extended Spectrum β-lactamase (ESBL)- and Carbapenemase-Expressing Enterobacteriaceae Isolated From Recent Urinary Tract Infections

Sarah McLeod, ASM Microbe 2018

Program(s): etx0282

Plasma and Intrapulmonary Concentrations of ETX2514 and Sulbactam in Healthy Adult Subjects

K.A. Rodvold (University of Illinois at Chicago), ASM Microbe 2018

Program(s): durlobactam (etx2514)

Presented at ID Week, San Diego, October 2017

Safety and Pharmacokinetics (PK) in Humans of Intravenous ETX2514, a β–lactamase Inhibitor (BLI) which Broadly Inhibits Ambler Class A, C, and D β–lactamases

J. Lickliter, K. Lawrence, J. O’Donnell, and R. Isaacs, ID Week 2017

Program(s): durlobactam (etx2514)